A Phase 3 interventional study of CTO0307 Eye drop and Vehicle (Placebo solution) in Presbyopia, sponsored by Taejoon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Taejoon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Presbyopia with a site in Korea, Republic of — none open to participants now, 1 under way, none of them phase 3. Presbyopia · Korea, Republic of.
Among the 10 studies in Presbyopia with a site in Korea, Republic of, this one has the largest enrollment, is the only one that started in 2025, is the only one in phase 3, and was the 10th registered.
336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.
Browse Presbyopia studies →None of the 10 studies in Presbyopia with a site in Korea, Republic of is open now. The open studies under Presbyopia, anywhere →
Of the 20 Presbyopia studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
This study's enrollment of 167 is above the median of 61 across 276 interventional studies indexed under Presbyopia.
Median enrollment 35 across the 10 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 7 most frequent:
Taejoon Pharmaceutical Co., Ltd. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Taejoon Pharmaceutical Co., Ltd. has 1 study filed under Presbyopia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Presbyopia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was to compare the presbyopia correction effect between the treatment group and the control group, evaluated by the proportion of patients who achieved an improvement of 3 lines or more in mesopic binocular DCNVA at post-dose after 4 weeks of administration of the investigational product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet all of the following visual acuity assessment criteria:
① DCNVA between 20/100 and 20/40 (Snellen equivalent).
② CDVA of 20/25 or better (Snellen equivalent).
Exclusion Criteria:
Patients with the following conditions known to require cautious administration of the investigational product components:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTO0307 Ophthalmic Solution
Drug: CTO0307 Eye drop
Vehicle
Drug: Vehicle (Placebo solution)
Pilocarpine ophthalmic solution, one drop in each eye, once daily, for up to 28 days
Vehicle, one drop in each eye, once daily, for up to 28 days.
Percentage of Participants Gaining 3 Lines or More in DCNVA
The proportion of patients who achieved an improvement of ≥3 lines from baseline in DCNVA (Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity) at post-dose
Time frame: Week 4
Percentage of Participants Gaining 2 Lines or More in DCNVA at Week 4
The proportion of patients who achieved an improvement of ≥2 lines from baseline in DCNVA (Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity) at post-dose
Time frame: Week 4
Percentage of Participants with DCNVA of >20/40 at Week 4
Percentage of Participants with DCNVA (Mesopic \& Photopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity) of \>20/40 from Baseline
Time frame: Week 4
Percentage of Participants with improvement in Patient Global Impression of Change (PGIC) at Week 4.
Patients assessed the impact of the IP on near vision improvement using the PGIC scale. After the investigator explained the assessment method, patients performed the evaluation independently based on their own judgment. 1. Very Much Improved 2. Much Improved 3. Minimally Improved 4. No change 5. Minimally Worse 6. Much Worse 7. Very Much Worse
Time frame: Week 4
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Sep 2025, 6 months.
Of 19 phase 3 interventional studies under Presbyopia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 11. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taejoon Pharmaceutical Co., Ltd. →